Announcement on Holding Subsidiary's Passing GMP Compliance Inspection
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Holding Subsidiary's Passing GMP Compliance Inspection
Filed with SSE · · 2 pages · Chinese
Release
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on 6ix
Earlier from Shanghai Fosun Pharmaceutical (Group)
- Announcement on Resolutions of the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026
- Announcement on New Drug Indication Obtaining Registration Approval for a Holding Subsidiary
- Announcement on Obtaining Approval of Drug Registration by the Holding Subsidiary
- Announcement on Progress in Participating in Setting up Private Equity Investment Fund
- Announcement on Outward Investment and Related Party Transactions
Later from Shanghai Fosun Pharmaceutical (Group)
- Announcement on Progress in Providing Guarantee for Holding Subsidiary
- Indicative Announcement on Obtaining EU Approval of a New Indication for a Drug Developed by the Holding Subsidiary
- Announcement on Progress in Transfer of Partnership Interests and Progress in Private Equity Investment Fund Invested by the Partnership
- Announcement on Resolutions of the 33rd (Extraordinary) Meeting of the 10th Board of Directors
- Announcement on Pledge of Partial Shares Held by a Shareholder
Follow Shanghai Fosun Pharmaceutical (Group) into a list and get an email when it puts out news.
Follow Shanghai Fosun Pharmaceutical (Group)